Table 4

Associations between therapeutic intensification therapy and incident cardiovascular disease in relation to the group receiving no additional therapy

		Risk for occurrence of any CVD
		Unadjusted			Adjusted
	Type of DM therapy	RR	95% CI	p Value	RR	95% CO	p Value
Patients with and without baseline CVD N=3331	Insulin	1.06	0.86 to 1.32	0.56	1.24	0.98 to 1.56	0.08
	GLP-1RA	0.44	0.24 to 0.82	0.01	0.53	0.28 to 0.99	0.048
	ODM	0.97	0.83 to 1.14	0.73	1.08	0.92 to 1.28	0.34
Patients without baseline CVD N=1394	Insulin	1.06	0.63 to 1.76	0.84	1.38	0.79 to 2.39	0.26
	GLP-1RA	0.25	0.06 to 1.03	0.055	0.30	0.07 to 1.24	0.096
	ODM	1.01	0.72 to 1.41	0.94	1.20	0.84 to 1.71	0.32
Patient with baseline CVD N=1937	Insulin	1.06	0.84 to 1.34	0.63	1.18	0.91 to 1.53	0.21
	GLP-1RA	0.53	0.26 to 1.07	0.08	0.64	0.31 to 1.30	0.21
	ODM	0.96	0.80 to 1.14	0.63	1.06	0.88 to 1.17	0.56

CVD, cardiovascular disease; DM, diabetes mellitus; GLP-1RA, glucagon like peptide-1 receptor agonist; ODM,oral diabetes medications.